Insider Buying: HCW Biologics (NASDAQ:HCWB) SVP Acquires $19,958.88 in Stock

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers bought 7,736 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average cost of $2.58 per share, with a total value of $19,958.88. Following the completion of the transaction, the senior vice president owned 8,691 shares in the company, valued at approximately $22,422.78. This trade represents a 810.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

HCW Biologics Price Performance

NASDAQ:HCWB opened at $3.20 on Monday. The company has a market capitalization of $5.12 million, a PE ratio of -0.06 and a beta of 2.32. HCW Biologics Inc. has a 52-week low of $1.50 and a 52-week high of $44.10. The stock’s 50 day moving average price is $6.50 and its 200 day moving average price is $5.18.

HCW Biologics (NASDAQ:HCWB) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($2.64) by $3.01. The company had revenue of $6.54 million during the quarter, compared to analysts’ expectations of $6.54 million. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics at the end of the most recent reporting period. Institutional investors own 2.96% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Maxim Group upped their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.